Notícias da área de saúde nos EUA

Tem $1,000? 2 Estoques que poderiam ser comprados a partir de 2022

Tem $1,000? 2 Estoques que poderiam ser comprados a partir de 2022

As 2022 draws to a close, it is safe to say Wall Street won’t remember this year fondly. Economic problems such as inflation, a persistent pandemic, and geopolitical tensions are some factors contributing to the broader market’s poor performance this year. No one can predict when equities will recover, but when they do, it will pay to have skin in the game.

Buying undervalued stocks today could help investors beat the market in the next five years and beyond. Let’s look at two biotech stocks that look attractive at current levels: AbbVie (NYSE: ABBV) e Gilead Ciências (NASDAQ: GILD) .

Continuar lendo

Para mais detalhes, veja:

Tem $1,000? 2 Estoques que poderiam ser comprados a partir de 2022

Artigos relacionados

Botão Voltar ao topo